Background: We observed that eupatilin, an active flavone derived from Artemisia plant species, functions as a PPAR メ activator through in vitro study. Objectives: We evaluated whether sequential application of topical eupatilin after topical glucocorticoid (GC) could be more effective than GC alone for AD lesion in AD murine model. Also, we conducted clinical trials to assess the efficacy and safety of Artemisia argyi extracts containing eupatilin for AD patients. Methods: In animal experiment, GC was applied on inflamed skin of hairless mice only in the first day of the experiment, with 3 subsequent consecutive days of treatment with eupatilin as well as bezafibrate as a positive control, or vehicle as a negative control. The efficacy of eupatilin was evaluated by gross feature and skin barrier function. For clinical study, thirty subjects were recruited and randomly applied with active cream (treated site) or vehicle cream (control site) to the left or right side of the whole body twice a day for 4 weeks. Treatment outcomes were assessed by EASI score, itch score and skin barrier function. Results: In the animal study, topical eupatilin improved eczema lesion and skin barrier function. In the clinical study, a significant decrease in the EASI and itch scores (p<0.05) was observed in the treated sites. The skin barrier function was also improved. Any remarkable side effects related with the active cream were not found. Conclusion: Topical application of eupatilin could improve AD lesions.